Physician profile
Youval Katz
NPI 1609052174
$1,031.71
in general payments reported to CMS, 2019-2025
21 companies · $667 in 2025
The $667 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2022: $26.00 · 2023: $29.03 · 2024: $42.46 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.95 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Celgene Corporation | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.49 | 2023-2024 | Opdualag, Opdivo |
| Genentech USA, INC. | $63.60 | 2025 | Phesgo, Polivy |
| Incyte Corporation | $52.04 | 2025 | Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $47.17 | 2025 | Ninlaro |
| Beone Medicines USA, INC. | $46.00 | 2025 | Tevimbra, Brukinsa |
| Taiho Oncology, INC. | $35.39 | 2025 | |
| Pharmacosmos Therapeutics INC. | $34.40 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $29.03 | 2025 | Ultomiris |
| Daiichi Sankyo INC. | $27.56 | 2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $27.46 | 2025 | |
| Pharming Healthcare, INC. | $26.00 | 2022 | |
| Pfizer INC. | $24.97 | 2025 | |
| Merck Sharp & Dohme LLC | $24.45 | 2025 | Keytruda Qlex, Keytruda |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $23.55 | 2025 | Orserdu |
| Array Biopharma INC | $23.40 | 2025 | Braftovi |
| Janssen Biotech, INC. | $21.40 | 2025 | Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $21.25 | 2025 | |
| Puma Biotechnology, INC. | $17.93 | 2025 | |
| Amgen INC. | $15.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youval Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.